Several novel serum inflammatory markers, including NLR, PLR, LMR, and C‐reactive protein (CRP), have been shown to predict the risk of tumor recurrence and metastasis, and to assess the survival probability of patients with advanced lung cancer.34, 35, 36, 37. This evidence concerns the gene CRP and lung cancer.